Sort
16,300 grants matching “fatty liver disease”
Tumor-promoting and tumor-suppressive roles of Hepatic Stellate Cell Subpopulations in NASH-HCC
$515,123Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2022 · CA
Nonalcoholic Steatohepatittis Clinical Research Network (NASH CRN)
$515,091Arun J Sanyal · Virginia Commonwealth University · U01 · FY2020 · DK
Role of estrogen receptor-a in aging and sex-specific responses to 17a-estradiol
$514,994Michael B Stout · Oklahoma Medical Research Foundation · R01 · FY2022 · AG
Accurate Measurement of Renal Function in Cirrhosis
$514,948Vivian S Lee · University Of Utah · R01 · FY2012 · DK
Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention
$514,929Robert E Gerszten · Beth Israel Deaconess Medical Center · R01 · FY2023 · NR
Lipid-Responsive E3 ubiquitin ligases in cholesterol metabolism and atheroscierosis
$514,800Peter J Tontonoz · University Of California Los Angeles · R01 · FY2021 · HL
Lipid-Responsive E3 ubiquitin ligases in cholesterol metabolism and atheroscierosis
$514,800Peter J Tontonoz · University Of California Los Angeles · R01 · FY2019 · HL
Lipid-Responsive E3 ubiquitin ligases in cholesterol metabolism and atheroscierosis
$514,800Peter J Tontonoz · University Of California Los Angeles · R01 · FY2020 · HL
Role of estrogen receptor-a in aging and sex-specific responses to 17a-estradiol
$514,707Michael B Stout · Oklahoma Medical Research Foundation · R01 · FY2021 · AG
Role of estrogen receptor-a in aging and sex-specific responses to 17a-estradiol
$514,469Michael B Stout · Oklahoma Medical Research Foundation · R01 · FY2024 · AG
Effect of Bariatric Surgery on Insulin Resistance and CVD
$514,462Anita P Courcoulas · University Of Pittsburgh At Pittsburgh · U01 · FY2007 · DK
Determining hepatocyte-specific mechanisms by which Ube4A regulates NAFLD/NASH
$514,249Anutosh Chakraborty · Saint Louis University · R01 · FY2023 · DK
Clinical utility of leptin therapy in syndromic forms of insulin resistance.
$513,817Rebecca Brown · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Hepatic TGFbeta1 in Control of Type 2 Diabetes and NASH via FoxO1 Signaling
$513,385Shaodong Guo · Texas A&M Agrilife Research · R01 · FY2023 · DK
Biology of the orphan receptor Rev-erb alpha
$513,370Mitchell A. Lazar · University Of Pennsylvania · R01 · FY2015 · DK
Dissecting the Role of Arachidonic Acid Metabolic Pathways Involved in Resolution Versus Progression of PM-Induced Cardiometabolic Toxicity
$513,320Jesus Antonio Araujo · University Of California Los Angeles · R01 · FY2024 · ES
Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention
$513,262Robert E Gerszten · Beth Israel Deaconess Medical Center · R01 · FY2025 · NR
Hepatic Steatosis Quantification with Ultrasound
$513,211Shigao Chen · Mayo Clinic Rochester · R01 · FY2023 · DK
Inhibition of hepatic (V)LDL production by a novel antagonist of carboxyl esterase 1
$512,957Stephen A Duncan · Medical University Of South Carolina · R01 · FY2024 · DK
Diet and Gene Effects on Atherosclerosis and CVD Risk
$512,913Michael C. Mahaney · Texas Biomedical Research Institute · P01 · FY2012 · HL
LIPOPROTEIN AND HYPERTENSION QTL CANDIDATE GENES
$512,913Laura A Cox · Texas Biomedical Research Institute · P01 · FY2012 · HL
Tissue Responses to Metabolic Stress
$512,774Jean E Schaffer · Washington University · R01 · FY2016 · DK
ABCA1, ApoAI and Reverse Cholesterol Transport
$512,595Jonathan D Smith · Cleveland Clinic Lerner Com-Cwru · P01 · FY2010 · HL
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents
$512,558Paul A. Johnston · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention
$512,548Robert E Gerszten · Beth Israel Deaconess Medical Center · R01 · FY2024 · NR